EP3153171
Samídórfan (ALKS 33) í samsetningu með búprenórfíni við að meðhöndla þunglyndisraskanir
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
14.12.2012EP published:
19.9.2018EP application number:
16201359.3
EP translation filed:
29.10.2018Grant published:
15.11.2018EPO information:
European Patent Register
Max expiry date:
13.12.2032Expiry date:
13.12.2023
Title:
SAMIDORPHAN (ALKS 33) IN COMBINATION WITH BUPRENORPHINE FOR THE TREATMENT OF DEPRESSIVE DISORDERS
Timeline
Today
14.12.2012EP application
19.9.2018EP Publication
29.10.2018Translation submitted
15.11.2018Registration published
13.12.2023Expires
Owner
Name:
Alkermes Pharma Ireland LimitedAddress:
Connaught House 1 Burlington Road, 4, Dublin, IE
Inventor
Name:
DEAVER, DanielAddress:
Franklin, Massachusetts, US
Name:
EHRICH, ElliottAddress:
Boston, Massachusetts, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201161576233 PDate:
15.12.2011Country:
US
Classification
Categories:
A61K 31/485, A61P 25/24, A61P 25/04
Annual fees
Number
Paid
Expires
Payer
Number: 7
Paid: 20.11.2018
Expires: 13.12.2019
Payer: Sigurjónsson & Thor ehf.
Number: 8
Paid: 19.11.2019
Expires: 13.12.2020
Payer: Sigurjónsson & Thor ehf.
Number: 9
Paid: 18.11.2020
Expires: 13.12.2021
Payer: Sigurjónsson & Thor ehf.
Number: 10
Paid: 18.11.2021
Expires: 13.12.2022
Payer: Sigurjónsson & Thor ehf.
Number: 11
Paid: 21.11.2022
Expires: 13.12.2023
Payer: Árnason Faktor ehf.